Malcisbo

Biotechnology, Health Care, Medical, Test and Measurement
Founded in 2010-01-01
Schlieren, Zurich, Switzerland
http://www.malcisbo.com/
For Profit

About Malcisbo

Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Their focus is on parasitic diseases, on human food safety and on zoonotic diseases. The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Combined with their glycoengineering technologies, novel and efficient glycoconjugate vaccines are being developed. Malcisbo is developing a strong pipeline of novel vaccine products coming out this platform for unmet needs in human and veterinary medicine targeting large markets. It is Malcisbo’s goal to develop affordable vaccines to protect people in underdeveloped areas against parasitic worm infections (e.g., helminthic infections by hookworm, filaria or schistosoma).

Company Metrics

  • Employees: 1-10
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 130000 CHF
  • Last Funding: 100000 CHF (Pre-Seed)
  • Funding Status: Seed

Technology Stack

Malcisbo actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Medical, Test and Measurement

Headquarters: Schlieren, Zurich, Switzerland